seen from China
seen from China
seen from Canada
seen from United States
seen from China
seen from Singapore
seen from United States
seen from China
seen from Singapore
seen from Colombia
seen from Singapore
seen from Bangladesh
seen from United States
seen from Thailand
seen from Germany
seen from China
seen from United States
seen from Netherlands
seen from Thailand
seen from Colombia
Great start last night at ACTRIMS conference in San Diego. Fun street painting with conference attendees helping collage in elements. Plus we were able to raise $2,600 to help fight MS for the Accelerated Cure Project. Today’s goal is to get to $10,000!!! And also to finish painting the wall! #imbalancingms #ms #msresearch #actrims #actrims2018 #art #anamorphicart #3dtrickart #conferenceart #medicalconference
It’s 2018 - some important events to watch out for this year
It’s 2018 – some important events to watch out for this year
Happy New Year to you all.
To get your year off to a good start, here are a few important dates for your new 2018 diary.
February 1 – 3
ACTRIMS Forum, San Diego, California, USA
The third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is themed “Therapeutic Targets in MS: The Frontier and the Future of Disease Modifying Therapy”.
Highlights of the…
View On WordPress
Ibudilast slows both brain shrinkage and loss of myelin in MS, phase 2 trial shows
Ibudilast slows both brain shrinkage and loss of myelin in MS, phase 2 trial shows
Multiple sclerosis organisations, and the media, are excited about new drug ibudilast. This follows a striking presentation at the ECTRIMS-ACTRIMS meeting in Paris.
So, what exactly is ibudilast and what can it do? Well, it’s an ant-inflammatory treatment but, for a more detailed answer, I am grateful to multiplescleroisnewstoday.com for this explanation:
“Ibudilast, labeled MN-166 by MediciNova
View On WordPress
New MS studies unveiled at Paris meeting
New MS studies unveiled at Paris meeting
Two reports from the multiple sclerosis get-together in Paris, held last week, caught my attention.
The session was a joint meeting of ECTRIMS and ACTRIMS, the European and Americas Committees for Treatment and Research in Multiple Sclerosis.
Both items from Paris are of special interest to me, as I have personal experience of them.
The first is news that, after the first round of symptoms, mult…
View On WordPress
